אירינוטקאן זריקות 20 מ"ג/מ"ל - Irinotecan injection 20 mg/ml
ש××× ×× !
×ת×ר××: 23/02/2019 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 23/02/2019 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01CE Topoisomerase 1 (TOP1) inhibitors | |||||
|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | ת××-×ר××× - I.V | |||||
| צ×רת ××× ×× | תר××× ×××× ×ª ת×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. For the treatment of patients with small cell lung cancer. For the treatment of patients with gastric cancer.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
Â
|
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | HOSPIRA UK LTD, UK |
| ×©× ××¢× ×ר×ש×× | TRUEMED LTD. |
| ר×ש××× | ת×ר×× ××ש×: 11/2005. ר×ש××× ×ת×ר××: 10/2017 |
| ת×ר×× ×¢×××× ××ר×× | 23/02/2019 |